Search research articles
Contact Us
Filters
Showing results (31-40 of 37) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 37 results.
Trials
|
October 26, 2019
Correction to: Choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial - the development of the DELTA2 guidance
William Sones, Steven A Julious, Joanne C Rothwell, et al.
British Journal of Cancer
|
February 14, 2018
A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma
Natalie Cook, Bristi Basu, Donna-Michelle Smith, et al.
BMC Medicine
|
March 2, 2018
Adaptive designs in clinical trials: why use them, and how to run and report them
Philip Pallmann, Alun W Bedding, Babak Choodari-Oskooei, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
March 24, 2021
Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa: An Open-Label, Randomized, Bayesian Noninferiority Trial
Paul A Brogan, Barbara Arch, Helen Hickey, et al.
Health Technology Assessment (Winchester, England)
|
October 30, 2019
Practical help for specifying the target difference in sample size calculations for RCTs: the DELTA<sup>2</sup> five-stage study, including a workshop
Jonathan A Cook, Steven A Julious, William Sones, et al.
Trials
|
November 8, 2018
DELTA<sup>2</sup> guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial
Jonathan A Cook, Steven A Julious, William Sones, et al.
Plos One
|
March 31, 2015
Elicitation of expert prior opinion: application to the MYPAN trial in childhood polyarteritis nodosa
Lisa V Hampson, John Whitehead, Despina Eleftheriou, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 37) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 37 results.
Trials
|
October 26, 2019
Correction to: Choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial - the development of the DELTA2 guidance
William Sones, Steven A Julious, Joanne C Rothwell, et al.
British Journal of Cancer
|
February 14, 2018
A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma
Natalie Cook, Bristi Basu, Donna-Michelle Smith, et al.
BMC Medicine
|
March 2, 2018
Adaptive designs in clinical trials: why use them, and how to run and report them
Philip Pallmann, Alun W Bedding, Babak Choodari-Oskooei, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
March 24, 2021
Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa: An Open-Label, Randomized, Bayesian Noninferiority Trial
Paul A Brogan, Barbara Arch, Helen Hickey, et al.
Health Technology Assessment (Winchester, England)
|
October 30, 2019
Practical help for specifying the target difference in sample size calculations for RCTs: the DELTA<sup>2</sup> five-stage study, including a workshop
Jonathan A Cook, Steven A Julious, William Sones, et al.
Trials
|
November 8, 2018
DELTA<sup>2</sup> guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial
Jonathan A Cook, Steven A Julious, William Sones, et al.
Plos One
|
March 31, 2015
Elicitation of expert prior opinion: application to the MYPAN trial in childhood polyarteritis nodosa
Lisa V Hampson, John Whitehead, Despina Eleftheriou, et al.
Page
of 4